BPIfrance and CEA Investissement both contribute cash to a series A round for the medical device company.
France-based medical device manufacturer Keranova has raised €4m ($4.55m) in a series A round co-led by CEA Investissement and Mérieux Développement, the corporate venturing unit of BioMérieux.
CEA Investissement is the investment arm of government-backed research organisation French Alternative Energies and Atomic Energy Commission (CEA). The subsidiary is also backed by France’s public investment bank BPIfrance, energy company EDF, BioMérieux and aircraft engine manufacturer Safran.
BPIfrance also contributed funds to the round.
Founded in 2015, Keranova is working on surgical instruments that reduce the need for manual intervention in ophthalmic surgery. The technology is based on research conducted at Jean Monnet University.
The money will go towards the development of a prototype and a preclinical study.
Valérie Calenda, partner at Mérieux Développement, said: “Keranova’s technological advances should improve the accuracy and efficiency of surgery for several ophthalmologic diseases.
“We are delighted to fund this high potential industrial project in the Rhône-Alpes region and to support a team that has experience in the development and commercialisation of innovative products.”
– This article first appeared on our sister site Global Government Venturing.
